Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus XIPERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM PHOSPHATE versus XIPERE.
HYDROCORTISONE SODIUM PHOSPHATE vs XIPERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium phosphate is a corticosteroid that binds to the glucocorticoid receptor, leading to regulation of gene transcription. It inhibits phospholipase A2, reducing pro-inflammatory mediators such as prostaglandins and leukotrienes. It also suppresses immune cell migration and cytokine production.
Triamcinolone acetonide is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes. It also decreases vascular permeability and inhibits cytokine release.
100-500 mg intravenously or intramuscularly every 2-6 hours as needed for acute conditions; typical dose 100 mg IV/IM every 8 hours.
The recommended dose is 0.1 mL (containing 0.16 mg triamcinolone acetonide injectable suspension) administered by suprachoroidal injection to the affected eye(s) once every 3 months (every 12 weeks).
None Documented
None Documented
Terminal elimination half-life approximately 1.5–2 hours; in adrenal insufficiency, dose interval is 8 hours due to HPA axis suppression considerations.
The terminal elimination half-life of triamcinolone acetonide following suprachoroidal administration is approximately 18 hours. This short half-life allows for sustained local effect with minimal systemic accumulation.
Renal: primarily as inactive metabolites, <1% unchanged; hepatic metabolism to tetrahydrocortisone and glucuronide conjugates; biliary/fecal excretion negligible.
XIPERE (triamcinolone acetonide injectable suspension) is primarily eliminated via hepatic metabolism and subsequent renal excretion of metabolites. Approximately 40% of the dose is excreted renally as metabolites, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for about 60% of the dose, mainly as metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid